188 completed, 49 recruiting, 48 terminated, 34 active not recruiting. 374 Phase 2, 106 Phase 1, 26 Phase 3.
Follow Sirolimus: new trials by email Literature Review of Sirolimus trials Research Report on Sirolimus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment Interruption Baricitinib 2 MG, Sirolimus 2 MG, Placebo of baricitinib 2 MG - HIV-1-infection | Phase 2 | Not yet recruiting | ANRS, Emerging Infectious Diseases | 191 | 2027-05-01 | 2026-10-19 |
| Ventricular mTOR Inhibition to Prevent Hydrocephalus After Brain Hemorrhage Sirolimus (Rapamune®) - Post-hemorrhagic Hydrocephalus (PHH) | Phase 1 / Phase 2 | Not yet recruiting | Massachusetts General Hospital | 15 | 2027-01-01 | 2026-06-25 |
| Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma Cemiplimab, Prednisone, Sirolimus - Kidney Transplant Recipient, Cutaneous Squamous Cell Carcinoma (CSCC) | Phase 2 | Not yet recruiting | Washington University School of Medicine | 22 | 2026-11-30 | 2026-10-15 |
| Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma Mirdametinib, Sirolimus - Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma (RRMM) | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 54 | 2026-11-19 | 2026-11-16 |
| Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-11-05 | 2026-10-08 |
| A Nutritional and Pharmacological Intervention for Body, Brain, and Longevity Effects (NIBBLE) FMD1 (LNT22-017-1), Rapamycin, Placebo - Cerebral Blood Flow, APOE 4 | Phase 1 / Phase 2 | Not yet recruiting | Cedars-Sinai Medical Center | 60 | 2026-11-01 | 2026-09-16 |
| Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE) Intestinal, Multivisceral or Modified Multivisceral Transplantation, Alemtuzumab, Tacrolimus - Secondary Malignant Neoplasm of Retroperitoneum, Secondary Malignant Neoplasm of Peritoneum | Phase 2 | Not yet recruiting | Case Comprehensive Cancer Center | 20 | 2026-11-01 | 2026-09-24 |
| A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies UB-VV400, Rapamycin (sirolimus) - Lymphoma, B Cell, Lymphoma Non-Hodgkin | Phase 1 / Phase 2 | Recruiting | Umoja Biopharma | 274 | 2026-11-01 | 2026-11-10 |
| Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors. Dinutuximab beta, Sirolimus and Irinotecan - Osteosarcomas, Bone Cancer | Phase 1 / Phase 2 | Not yet recruiting | University Hospital, Strasbourg, France | 89 | 2026-10-01 | 2026-10-01 |
| Sirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNI Sirolimus, Ruxolitinib, MMF - Acute Leukemia, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Not yet recruiting | Peking University People's Hospital | 40 | 2026-10-01 | 2026-09-09 |
| Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease Cyclophosphamide 50mg, Abatacept, Alemtuzumab - Sickle Cell Disease | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 45 | 2026-09-10 | 2026-11-12 |
| Safety Study for the Use of Rapamycin in Children With Familial Adenomatous Polyposis Rapamycin - Familial Adenomatous Polyposis | Phase 2 | Not yet recruiting | University Hospital, Toulouse | 25 | 2026-09-01 | 2026-05-08 |
| A Phase 2 Study of Sirolimus for Injection (Albumin-bound) in Patients With Progressive or Symptomatic Epithelioid Hemangioendothelioma Sirolimus for injection (Albumin-bound) - Epithelioid Hemangioendothelioma | Phase 2 | Not yet recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 40 | 2026-08-01 | 2026-07-06 |
| Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma Domatinostat, Sirolimus - Sarcoma, Osteosarcoma | Phase 1 / Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 74 | 2026-07-15 | 2026-09-03 |
| Low- vs High-Dose Sirolimus With Prednisolone for KHE and KMP Sirolimus (RAPAMUNE) - Kaposiform Hemangioendothelioma (KHE), Kasabach Merritt Phenomenon | Phase 2 / Phase 3 | Recruiting | Yi Ji | 76 | 2026-06-16 | 2026-06-18 |
| Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia Sirolimus, Placebo - Systemic Lupus Erythematosus, Immune Thrombocytopenia | Phase 2 / Phase 3 | Recruiting | Chinese SLE Treatment And Research Group | 164 | 2026-06-07 | 2026-06-18 |
| Vertebrobasilar Dolichoectasia Treatment With Sirolimus Sirolimus - Vertebrobasilar Dolichoectasia | Phase 2 | Not yet recruiting | Huashan Hospital | 12 | 2026-06-01 | 2026-06-08 |
| A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) INCA034176, Best available Treatment (BAT) - Chronic Graft-versus-host-disease | Phase 2 | Recruiting | Incyte Corporation | 60 | 2026-05-20 | 2026-11-13 |
| MTOR Inhibitors in Older Adults Sirolimus 0.5 Mg Oral Tablet, Sirolimus 1Mg Oral Tablet, Sirolimus 2 MG Oral Tablet - Aging | Phase 1 / Phase 2 | Recruiting | University of Texas Southwestern Medical Center | 60 | 2026-05-11 | 2026-06-25 |
| Vaccination Response Modulation With a Targeted Rapamycin Protocol Study Sirolimus (RAPAMUNE), Influenza vaccine (Sequiris Fluad Quad), RSV vaccine (Pfizer Abrysvo) - Vaccine Immune Response, Haemodialysis Patients | Phase 2 | Not yet recruiting | Central Adelaide Local Health Network Incorporated | 60 | 2026-05-01 | 2026-05-14 |
Showing 20 of 374. Sign in to see all of them.
Graft vs Host Disease (38) · Myelodysplastic Syndromes (26) · Leukemia, Myeloid, Acute (25) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (24) · Lymphoma, Non-Hodgkin (22) · Anemia, Sickle Cell (19) · Hodgkin Disease (18) · Leukemia, Lymphocytic, Chronic, B-Cell (18) · Multiple Myeloma (18) · Leukemia (15) · Hematologic Neoplasms (14) · Lymphoma, Mantle-Cell (14) · Sarcoma (14) · Diabetes Mellitus, Type 1 (13) · Lymphoma, Large B-Cell, Diffuse (13)
National Cancer Institute (NCI) (53) · National Institute of Allergy and Infectious Diseases (NIAID) (18) · Fred Hutchinson Cancer Center (11) · Dana-Farber Cancer Institute (9) · National Heart, Lung, and Blood Institute (NHLBI) (8) · City of Hope Medical Center (6) · H. Lee Moffitt Cancer Center and Research Institute (6) · National Eye Institute (NEI) (6) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (5) · Masonic Cancer Center, University of Minnesota (5) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (5) · Peking University People's Hospital (5) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (5) · Stanford University (5) · West China Hospital (5)
United States (262) · China (26) · Canada (19) · Italy (14) · France (11) · Spain (10) · Germany (7) · United Kingdom (6) · Australia (5) · Belgium (5) · South Korea (5) · Sweden (4) · Denmark (3) · Netherlands (3) · New Zealand (3)
Elizabeth M Kang, M.D. (5) · Christopher G Kanakry, M.D. (4) · Joel Naor, MD (4) · Damiano Rondelli, MD (3) · Laura Johnston (3) · Lorenzo Piemonti, MD (3) · Yi Ji, MD, PhD (3) · AeRang Kim, MD, PhD (2) · Aldo T Iacono, MD (2) · Arun Rajan, M.D. (2) · Brenda Sandmaier (2) · Brigitte Widemann, MD (2) · Corey Cutler, MD, MPH (2) · Courtney F Joseph, M.D. (2) · Edwin P. Alyea, MD (2)
PMID 36240296, PMID 35030255, PMID 42133908, PMID 28486787, PMID 31489702, PMID 32014025, PMID 39356039, PMID 22871490, PMID 30270358, PMID 33580918, PMID 34273457, PMID 34524406, PMID 35254001, PMID 39831682, PMID 40010689, PMID 40107509, PMID 41114938, PMID 41871072, PMID 12176626, PMID 12176628, PMID 15233820, PMID 15257060, PMID 16407509, PMID 17005949, PMID 17090654, PMID 17510057, PMID 18184959, PMID 18215105, PMID 18416737, PMID 18997171, PMID 19127265, PMID 19167681, PMID 19192962, PMID 19208097, PMID 19238149, PMID 19539216, PMID 19562254, PMID 19663893, PMID 19710204, PMID 19950289, PMID 20007560, PMID 20107229, PMID 20501622, PMID 20664591, PMID 20837940, PMID 20847709, PMID 21084848, PMID 21135251, PMID 21314851, PMID 21403127
P30CA015704 (8), U10CA025224 (6), N01CM00071 (5), N01CM62201 (5), U10CA027469 (5), N01CM00038 (4), P30CA006973 (4), P30CA014599 (4), P30CA033572 (4), U10CA021115 (4), 2018 (3), 2025 (3), N01CM00099 (3), N01CM62202 (3), N01CM62207 (3)